Reduction of vascular leakage, hyperreflective foci greater with faricimab

Dr. Jordan M. Graff, MD, FACS, presented a post hoc analysis of the YOSEMITE and RHINE clinical trials at Retina 2024, evaluating biomarkers for vascular stability. The trials compared faricimab vs. aflibercept in patients with diabetic macular edema, and found that faricimab showed a greater reduction in hyperreflective foci and vascular leakage. This suggests that dual Ang-2/VEGF-A inhibition with faricimab in phase 3 trials for DME demonstrates the benefit of biomarkers for vascular stability and inflammation. Dr. Graff reported receiving research support from Genentech and Regeneron.

Source link

error: Content is protected !!